NJIT Biomedical Engineering Student Highlights Rare Colon Cancer in Groundbreaking Research

In the realm of colorectal malignancies, one rare yet highly aggressive variant demands greater scientific scrutiny: squamous cell carcinoma (SCC) of the colon. Although colon cancer ranks among the most prevalent cancers in the United States, with over 100,000 new cases yearly, SCC of the colon represents a mere 0.02% to 0.1% of all colon cancers, making it an enigma in oncology. This subtype originates from squamous epithelial cells, which are atypical in the colon’s mucosal lining, setting it apart from the more common adenocarcinomas. The rarity of colorectal SCC, coupled with delayed symptomatology that mimics other colorectal pathologies, has posed significant hurdles to timely diagnosis and effective treatment.

The clinical veil surrounding SCC of the colon is further compounded by the scarcity of comprehensive case studies. Currently, fewer than 100 documented instances exist in medical literature, rendering the medical community’s understanding fragmented and the treatment paradigms inconsistent. This fragmentation hinders the establishment of standardized diagnostic protocols or therapeutic regimens, often relegating care to case-by-case decision-making. Addressing this critical gap, Eesha Oza, an undergraduate biomedical engineering student at New Jersey Institute of Technology (NJIT), spearheaded an investigative review aimed at consolidating existing knowledge to pave the way for more unified clinical approaches.

Oza’s research, published in the prestigious journal Frontiers in Oncology, highlights a compelling case of a 72-year-old woman diagnosed with colorectal SCC, who remarkably achieved long-term remission following surgical resection and adjuvant chemotherapy. During her extensive review of over six decades of reported cases—from 1955 through 2025—Oza was struck by the heterogeneity and disjointed nature of existing data, which largely consists of isolated single-patient reports. This lack of cohesive understanding epitomizes the challenges faced by clinicians in formulating evidence-based treatment strategies and underscores the urgency of compiling comprehensive datasets.

One of the most salient findings in Oza’s review pertains to the pivotal role of advanced imaging modalities in the early detection and accurate staging of colorectal SCC. Techniques such as contrast-enhanced computed tomography (CT) and positron emission tomography (PET) scans emerged as indispensable tools not only in identifying the primary tumor but also in assessing metastasis and differentiating SCC from other colorectal pathologies. These imaging technologies provide clinicians with critical insights into tumor morphology, local invasion, and distant spread, which are vital parameters influencing therapeutic decision-making.

The conventional management of colorectal SCC leans heavily on surgical intervention, with resection of the primary lesion forming the cornerstone of therapy. Chemotherapy, although typically reserved for advanced stages, has gained prominence as an adjunct treatment to reduce recurrence risk and manage residual disease. Nevertheless, the absence of a well-defined etiology for colorectal SCC complicates efforts to optimize therapy. Unlike adenocarcinomas, squamous cells are normally absent in colorectal mucosa, leaving the genesis of this cancer subtype shrouded in mystery with hypotheses ranging from metaplastic transformation of glandular epithelium to pluripotent stem cell differentiation, none of which have been conclusively validated.

Early diagnosis remains the linchpin for improved survival outcomes in colorectal malignancies. For patients with conventional colon cancer, a diagnosis at an early stage can yield a five-year survival rate approaching 90%. However, if the disease invades contiguous organs or metastasizes, survival rates precipitously decline to approximately 73% and below 16%, respectively. These bleak statistics underscore the urgent need for heightened clinical vigilance and improved screening protocols, particularly given that SCC symptoms often manifest late in disease progression, thus narrowing the therapeutic window.

Oza’s work advocates for a paradigm shift in how colorectal SCC is perceived and managed by emphasizing the value of pattern recognition across disparate case reports. Through systematic comparison and data assimilation, emergent trends can inform personalized treatment plans while aligning them with outcomes documented in prior cases. This granular understanding could ultimately translate into more precise prognostic indicators, tailored chemotherapeutic regimens, and potentially novel therapeutic targets.

Moreover, the application of biomedical engineering principles and techniques in cancer research is exemplified by Oza’s background and contributions. Utilizing computational modeling, imaging analytics, and biomolecular insights, biomedical engineers can help unravel the complex tumor microenvironment and the behavior of atypical cancer cells such as those seen in SCC. This interdisciplinary approach promises to integrate technological innovation with clinical oncology, potentially accelerating breakthroughs in diagnostics and therapeutics.

The case highlighted by Oza involved a patient who had not undergone standard colon cancer screening, a factor that likely contributed to the delayed diagnosis. This aspect highlights a broader public health challenge surrounding compliance with screening guidelines. For rare cancers like colorectal SCC, enhancing awareness among at-risk populations and healthcare providers is essential to facilitate early detection practices.

Research into rare cancer types, including SCC of the colon, also brings to light the limitations of current tumor classification systems that are predominantly designed around prevalent cancer types. Revisiting and refining these classification schemas to accommodate rare histopathological variants could improve diagnostic precision and foster the development of specialized treatment guidelines.

Future research directions prompted by Oza’s study include molecular profiling of colorectal SCC to identify potential biomarkers and genetic drivers unique to this histology. Such knowledge could reveal susceptibility pathways and therapeutic vulnerabilities, ultimately paving the way for targeted therapies and immunotherapies that have revolutionized treatment in other malignancies.

Despite the innovations and insights gained, the battle against colorectal SCC remains arduous, characterized by a paucity of cases, elusive pathogenesis, and variable clinical outcomes. Collaborative efforts combining clinical data aggregation, multidisciplinary research, and technological innovation are paramount to unraveling this cancer’s complexities. Oza’s contribution marks a meaningful stride towards consolidating fragmented knowledge and fostering a roadmap for improved diagnosis and management.

In summation, the enigma of squamous cell carcinoma of the colon underscores the critical need for focused research on rare cancers, where the low incidence belies their clinical severity. As technology advances and more comprehensive data become accessible, the hope is to transition from isolated anecdotes to evidence-based care pathways, improving prognosis for patients afflicted by this rare but formidable disease.